In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to EAPC Ivory (& above) Members, Fellows of the ESC and Young combined Members

Impact of erectile dysfunction on the severity of systemic inflammation in patients undergoing coronary artery bypass grafting

Session Poster Session III - Saturday 08:30 - 12:30

Speaker Olga Barbarash

Congress : EuroPrevent 2017

  • Topic : preventive cardiology
  • Sub-topic : Risk Factors and Prevention
  • Session type : Poster Session
  • FP Number : 763

Authors : S Pomeshkina (Kemerovo,RU), E Pomeshkin (Kemerovo,RU), E Velikanova (Kemerovo,RU), O Barbarash (Kemerovo,RU)

Authors:
S Pomeshkina1 , E Pomeshkin2 , E Velikanova1 , O Barbarash1 , 1Federal State Budgetary Institution Research Institute for Complex Issues of Cardiovascular Diseases - Kemerovo - Russian Federation , 2Municipal Budget Healthcare Institution “City Clinical Hospital # 3 n.a. M.A. Podgorbunskiy” - Kemerovo - Russian Federation ,

Citation:
European Journal of Preventive Cardiology ( April 2017 ) 24 ( Supplement 1 ), 169

Purpose: To assess the impact of erectile dysfunction (ED) on the severity of systemic inflammation in patients undergoing coronary artery bypass grafting (CABG).
Methods: 117 male patients with stable coronary artery disease (CAD) aged 55.8 ± 5.3 years undergoing elective on-pump CABG were included in a case-control study. All patients were assigned to two groups according to the results of the "International Index of Erectile Function" questionnaire, nocturnal penile tumescence (NPT) test, and duplex scanning of penile arteries: Group 1 (n=60) - patients with ED, and Group 2 (n=57) - patients with preserved erectile function. Patients were assessed 7 days prior to CABG, and 1, 6 months and one year after CABG. Levels of C-reactive protein (CRP) and tumor necrosis factor (TNF) were measured by the ELISA in all patients to evaluate systemic inflammation. The statistical analysis was conducted using the software Statistica 6.0. p <0.05 was considered statistically significant.
Results: The analysis of perioperative levels of blood inflammatory markers in CAD patients showed that CRP levels in patients with ED did not significantly change within 1 year after CABG. 1 month after CABG, the studied parameter did not change significantly in patients without ED (from 3.7 (2.6; 11.9) to 4.2 (2.7; 13.7) mg / l, p≥0.05). However, CRP levels decreased 6 months and 1 year after CABG compared to the preoperative levels (from 3.7 (2.6; 11.9) to 2.5 (1.9; 10.5) mg/l, p = 0.04 and from 3.7 (2.6; 11.9) to 3.0 (2.1; 10.7) mg/l, p = 0.04, respectively). While CRP levels were similar between the study groups in the preoperative period and 1 month after CABG, CRP levels 6 months and 1 year after CABG were higher in patients with ED, compared to patients with preserved erectile function (6.2 (3.5, 13.4) vs. 2.5 (1.9; 10.5) mg/l, p = 0.04, and 5.9 (3.1; 13.8) vs. 3.0 (2.1; 10.7) mg/l, p = 0.04, respectively). Blood levels of TNF-α at baseline, 1 month and 6 months after CABG were similar in both groups. However, patients without ED demonstrated a decrease in TNF-α levels 6 month after CABG compared to baseline levels (from 36.8 (22.4; 46.3) to 29.4 (20.6; 39.7) mg/l). 1 year after CABG this group of patients had significantly lower TNF-α levels compared to the baseline levels (from 36.8 (22.4; 46.3) to 27.6 (19.6; 38.1) mg/l; p = 0.04). Moreover, patients without ED had lower TNF-α levels than those in patients with ED at baseline, 6 months and 1 year after CABG (36.8 (22.4; 46.3) vs. 44.7 (31.4; 55.1) mg/l, p = 0.03; 29.4 (20.6; 39.7) vs. 40.1 (29.6; 51.4) mg/l; p= 0.01, and 27.6 (19.6; 38.1) vs. 37.5 (23.7; 42.3) mg/l, p = 0.04, respectively).
Conclusion: Erectile dysfunction in CAD patients worsens the severity of systemic inflammation in patients undergoing CABG.

The free consultation period for this content is over.

It is now only available year-round to EAPC Ivory (& above) Members, Fellows of the ESC and Young combined Members



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are